Phase III results for the Combo Dual Therapy Stent for CAD - Orbus Neich
Orbus Neich has announced long-term results from its REMEDEE Trial of the COMBO Dual Therapy Stent for patients with Coronary Artery Disease. In addition to showing that the stent shows no late target lesion revascularization, the results demonstrate that the stent proactively promotes functional vessel healing.
Key findings include the facts that target lesion revascularization remained stable at 5.7 percent in both years two and three of the follow up on the REMEDEE trial. In addition, there were no thrombotic events over three years. Complete polymer degradation and drug release by 90 days were also observed. Results were released during EuroPCR 2014.
Related news and insights
Fabhalta is a Factor B inhibitor that acts proximally in the alternative complement pathway of the immune system, providing comprehensive control of red blood cell (RBC) destruction within and outside the blood vessels (intra- and extravascular hemolysis [IVH and EVH])
Merck KGaA, a leading science and technology company, announced that its two Phase III EVOLUTION clinical trials (evolution RMS 1 and evolution RMS 2) investigating the efficacy and safety of evobrutinib did not meet their primary endpoints of reducing annualized relapse rates (ARR) in people with relapsing multiple sclerosis (RMS) compared to oral teriflunomide (Aubagio) (0.11 vs. 0.11 in evolution RMS 1 and 0.15 for evobrutinib vs. 0.14 for teriflunomide in evolution RMS 2, p=NS in both trials)